Margaret Tawadrous
Pfizer (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Resistance in Bacteria, Antifungal resistance and susceptibility, HIV/AIDS Research and Interventions
Most-Cited Works
- → Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial(2015)390 cited
- → Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection(2008)359 cited
- → Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection(2010)265 cited
- → Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review(2021)96 cited
- → Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa(2021)80 cited
- → Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial(2019)69 cited
- → Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial(2023)67 cited
- → Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial(2019)67 cited
- → Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial(2023)53 cited
- → Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies(2013)49 cited